Selected article for: "ARDS respiratory distress syndrome and efficacy safety"
Author: Xiong, Jing; Chen, Long; Zhang, Li; Bao, Lei; Shi, Yuan
Title: Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Severe COVID-19
  • Cord-id: c82y9q8a
  • Document date: 2021_3_2
    • ID: c82y9q8a
    Snippet: During the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many critically ill patients died of severe pneumonia, acute respiratory distress syndrome (ARDS), or multiple organ dysfunction syndrome. To date, no specific treatments have been proven to be effective for coronavirus disease 2019 (COVID-19). In the animal models and clinical applications, mesenchymal stromal/stem cells (MSCs) have been shown safety and efficacy for the treatment of respiratory virus infection
    Document: During the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), many critically ill patients died of severe pneumonia, acute respiratory distress syndrome (ARDS), or multiple organ dysfunction syndrome. To date, no specific treatments have been proven to be effective for coronavirus disease 2019 (COVID-19). In the animal models and clinical applications, mesenchymal stromal/stem cells (MSCs) have been shown safety and efficacy for the treatment of respiratory virus infection through their abilities of differentiation and immunomodulation. Besides, possessing several advantages of MSC-derived extracellular vesicles (EVs) over MSCs, EV-based therapy also holds potential therapeutic effects in respiratory virus infection. In this review, we summarized the basic characteristics and mechanisms of COVID-19 and MSCs, outlined some preclinical and clinical studies of MSCs or MSC-EVs for respiratory virus infection such as influenza virus and SARS-CoV-2, shed light on the common problems that we should overcome to translate MSC therapy into clinical application, and discussed some safe issues related to the use of MSCs.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and acute cardiac injury: 1, 2
    • abdominal pain and acute kidney injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain and acute phase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • abdominal pain and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • abdominal pain and acute toxicity: 1, 2
    • abdominal pain and adipose tissue: 1, 2, 3
    • abnormal coagulation and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5
    • abnormal coagulation and acute cardiac injury: 1
    • abnormal coagulation and acute kidney injury: 1, 2, 3
    • abnormal coagulation and acute phase: 1, 2
    • abnormal coagulation and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
    • absolute lymphocyte count and acute ards respiratory distress syndrome: 1, 2
    • absolute lymphocyte count and acute cardiac injury: 1
    • absolute lymphocyte count and acute kidney injury: 1, 2, 3
    • absolute lymphocyte count and acute phase: 1
    • absolute lymphocyte count and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • absolute neutrophil count and acute kidney injury: 1
    • absolute neutrophil count and acute phase: 1, 2, 3, 4, 5, 6
    • absolute neutrophil count and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15